LFCR icon

Lifecore Biomedical

6.77 USD
+0.06
0.89%
Updated Jun 20, 12:34 PM EDT
1 day
0.89%
5 days
1.20%
1 month
2.11%
3 months
2.89%
6 months
-6.49%
Year to date
1.65%
1 year
32.75%
5 years
-32.30%
10 years
-53.69%
 

About: Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.

Employees: 524

0
Funds holding %
of 7,302 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 4

53% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 19

13% more funds holding

Funds holding: 76 [Q4 2024] → 86 (+10) [Q1 2025]

1.2% less ownership

Funds ownership: 67.39% [Q4 2024] → 66.19% (-1.2%) [Q1 2025]

6% less capital invested

Capital invested by funds: $203M [Q4 2024] → $190M (-$12.5M) [Q1 2025]

11% less call options, than puts

Call options by funds: $24K | Put options by funds: $27K

14% less funds holding in top 10

Funds holding in top 10: 7 [Q4 2024] → 6 (-1) [Q1 2025]

Research analyst outlook

We haven’t received any recent analyst ratings for LFCR.

Financial journalist opinion

Based on 16 articles about LFCR published over the past 30 days

Positive
Seeking Alpha
2 days ago
Lifecore Biomedical: Inflecting Financials Over Next 3 Years
Lifecore Biomedical is emerging from a challenging restructuring and is now a pure play CDMO with new management, an improved balance sheet, expanded capacity, and a solid business plan. Industry dynamics and recent M&A suggest a decent chance of a near-term acquisition, potentially valuing LFCR at 2x its current price. LFCR's growth runway and customer stickiness support its premium valuation, but risks include easing capacity constraints and an uncertain exit multiple.
Lifecore Biomedical: Inflecting Financials Over Next 3 Years
Neutral
Accesswire
3 days ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect
Neutral
GlobeNewsWire
3 days ago
Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer
CHASKA, Minn., June 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a new 10-year commercial manufacturing and supply agreement with a key existing customer.
Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer
Neutral
Accesswire
5 days ago
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation
Neutral
GlobeNewsWire
1 week ago
Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale
Fortifies Balance Sheet and Reinforces Disciplined Capital Management Approach Fortifies Balance Sheet and Reinforces Disciplined Capital Management Approach
Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out
Neutral
Accesswire
2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation
Neutral
Accesswire
2 weeks ago
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR.
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Charts implemented using Lightweight Charts™